Get the Stockscreener App
0.30
4.90%
0.014
After Hours:
.30
Medicus Pharma Ltd stock is traded at $0.30, with a volume of 785.02K.
It is up +4.90% in the last 24 hours and down -11.50% over the past month.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
See More
Previous Close:
$0.286
Open:
$0.2872
24h Volume:
785.02K
Relative Volume:
0.13
Market Cap:
$17.00M
Revenue:
-
Net Income/Loss:
$-27.04M
P/E Ratio:
-0.152
EPS:
-1.9743
Net Cash Flow:
$-17.53M
1W Performance:
-0.33%
1M Performance:
-11.50%
6M Performance:
-85.92%
1Y Performance:
-95.76%
1-Day Range:
$0.286
$0.31
1-Week Range:
$0.268
$0.31
52-Week Range:
$0.25
$7.73
Medicus Pharma Ltd Stock (MDCX) Company Profile
Name
Medicus Pharma Ltd
Sector
Industry
Phone
610-540-7515
Address
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
0.30 | 16.20M | 0 | -27.04M | -17.53M | -1.9743 |
LLY
Lilly Eli Co
|
1,065.00 | 928.88B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
234.34 | 557.82B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
215.70 | 378.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
122.41 | 286.20B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
187.03 | 294.27B | 60.48B | 10.40B | 8.05B | 3.3297 |
Medicus Pharma Ltd Stock (MDCX) Latest News
MDCX Should I Buy - Intellectia AI
Medicus Pharma Ltd (MDCX) Stock Price, Quote, News & History - Benzinga
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - Chillicothe Gazette
New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medi - ACCESS Newswire
MDCX Stock Price, Quote & Chart | MEDICUS PHARMA LTD (NASDAQ:MDCX) - ChartMill
MDCX Technical Analysis | Trend, Signals & Chart Patterns | MEDICUS PHARMA LTD (NASDAQ:MDCX) - ChartMill
Medicus Pharma Ltd. (MDCXW) Reports FDA Progress and Expands 2026 Clinical Outlook - Insider Monkey
User - The Chronicle-Journal
Small cap wrap: Digi Power X, New Era Energy & Digital, 374Water, Medicus Pharma… - Proactive financial news
Medicus Pharma (Nasdaq: MDCX) Advances Lead Skin Cancer Regimen - MyChesCo
Medicus Pharma sees catalyst-rich year ahead as SkinJect and Teverelix progress - Yahoo Finance
MSN Money - MSN
MDCX Stock Chart | MEDICUS PHARMA LTD (NASDAQ:MDCX) - ChartMill
Medicus Pharma 1Q Loss/Shr 31c >MDCX - Moomoo
Medicus Pharma Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Medicus Pharma (MDCX) registers 3.25M shares as warrants remain exercisable - Stock Titan
Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Medicus Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Medicus Pharma (NASDAQ: MDCX) flags going concern as Q1 loss widens - Stock Titan
Skin cancer microneedle, prostate drug progress as Medicus loses $9M - Stock Titan
TradingKey - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
New to The Street Broadcasts Show #752 on Bloomberg Television Featuring Graphene Manufacturing Group (OTCQX:GMGRF), T-REX Acquisition Corp (NASDAQ:TRXA), KITON, and Roadzen (NASDAQ:RDZN) - Moomoo
Medicus Pharma Ltd expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Maxim Group Maintains Medicus Pharma(MDCX.US) With Buy Rating, Maintains Target Price $2 - Moomoo
Medicus Pharma Reports Expanded Phase 2 Skin Cancer Trial Data - MyChesCo
EXCLUSIVE: Medicus Sees Strongest Efficacy At Higher Dose In Skin Cancer Study - Sahm
Market movers: Uber, Super Micro Computer, Medicus Pharma, Arizona Gold & Silver, Hut 8... - Proactive financial news
Medicus Pharma reports strong Phase 2 dose response in skin cancer study - Proactive financial news
Medicus Pharma reports dose response data from skin cancer study By Investing.com - Investing.com India
Medicus Pharma reports dose response data from skin cancer study - Investing.com UK
Medicus Pharma highlights positive dose-response in updated skin cancer trial results - Yahoo Finance
$Medicus Pharma (MDCX.US)$ - Moomoo
Skin cancer study points to higher-dose winner with 55% response - Stock Titan
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response - ChartMill
Ajay Raju and Togo PHL entities report 2.03M shares in Medicus Pharma (MDCX) - Stock Titan
Medicus Pharma Meets Lawmakers to Advance SkinJect Program - MyChesCo
[ARS] Medicus Pharma Ltd. SEC Filing - Stock Titan
Medicus reports Phase 2 basal cell carcinoma trial results By Investing.com - Investing.com India
MDCX Forecast, Price Target & Analyst Ratings | MEDICUS PHARMA LTD (NASDAQ:MDCX) - ChartMill
MDCX SEC FilingsMedicus Pharma Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Medicus Pharma on Bloomberg World - Public Opinion
Medicus Pharma 2025 Executive Compensation, Board Governance, and Equity Incentive Plan Overview - Minichart
Medicus Pharma (Nasdaq: MDCX) details board structure and leadership pay - Stock Titan
Exclusive: Medicus Pharma refines trial design to cut costs, accelerate development for enlarged prostate patients - MSN
10-K/A: Annual report (Amendment) - Moomoo
MDCXW Price History for Medicus Pharma Ltd WT Stock - Barchart.com
Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndrome - Yahoo! Finance Canada
Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill - The Manila Times
Medicus Pharma Ltd Stock (MDCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
2.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):